Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
To provide oral domperidone to patients between the ages of 18 and 60 years of age, according
to the investigator's judgment, a prokinetic effect is needed for the relief of severe
gastroparesis. We have defined severe gastroparesis as 1) positive gastric emptying
scintigraphy (more than 10% residue at 4 hours), 2) nausea, 3) early satiety, 4) abdominal
pain. We will recruit patients for two years and the patients will be given domperidone for
up to two years.